Herpes simplex virus and HIV: Genital infection synergy and novel approaches to dual prevention

International Journal of STD and AIDS

Volumn 23, Issue 9, 2012, Pages 613-619

  Thurman, A R ^a   Doncel, G F ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Genital; Herpes simplex virus; HIV; HSV; Mucosal immunity; Mucosal inflammation; Prevention technologies

Indexed keywords

ACICLOVIR; TENOFOVIR; VALACICLOVIR;

DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MEGADOSE; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; INFLAMMATION; INNATE IMMUNITY; MIXED INFECTION; MUCOSAL IMMUNITY; PRIORITY JOURNAL; REVIEW;

ACYCLOVIR; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS;

EID: 84867046708     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2012.011356     Document Type: Review

References (79)

1. Xu F, Sternberg MR, Gottlieb SL, et al. Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years-United States, 2005-2008. MMWR Morb Mortal Wkly Rep 2010;59:456-9
2. Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 2004;190:1374-81
3. Mertz GJ, Schmidt O, Jourden JL, et al. Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis 1985;12:33-9
4. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11-20
5. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347:1652-61
6. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 2004;11(Suppl. 1):24A-35A
7. Lama JR, Lucchetti A, Suarez L, et al. Association of herpes simplex virus type infection and syphilis with human immunodeficiency virus infection among men who have sex with men in Peru. J Infect Dis 2006;194:1459-66
8. Rebbapragada A, Wachihi C, Pettengell C, et al. Negative mucosal synergy between herpes simplex type 2 and HIV in the female genital tract. AIDS 2007;21:589-98
9. Kaul R, Kimani J, Nagelkerke NJ, et al. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA 2004;291:2555-62
10. John M, Keller MJ, Fam EH, et al. Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis 2005;192:1731-40
11. Baeten JM, Strick LB, Lucchetti A, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 2008;198:1804-8
12. Dunne EF, Whitehead S, Sternberg M, et al. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV-and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 2008;49:77-83
13. Lingappa JR, Baeten JM, Wald A, et al. Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 2010;375:824-33
14. Van de Perre P, Segondy M, Foulongne V, et al. Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infect Dis 2008;8:490-7
15. Zhu J, Koelle DM, Cao J, et al. Virus-specific CD8{thorn} T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007;204:595-603
16. Zhu J, Hladik F, Woodward A, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009;15:886-92
17. Fakioglu E, Wilson SS, Mesquita PM, et al. Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J Virol 2008;82:9337-44
18. Goodkin ML, Ting AT, Blaho JA. NF-kappaB is required for apoptosis prevention during herpes simplex virus type 1 infection. J Virol 2003;77:7261-80
19. Amici C, Belardo G, Rossi A, Santoro MG. Activation of I kappa b kinase by herpes simplex virus type 1. A novel target for anti-herpetic therapy. J Biol Chem 2001;276:28759-66
20. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995;96:456-64
21. Al-Harthi L, Spear GT, Hashemi FB, Landay A, Sha BE, Roebuck KA. A human immunodeficiency virus (HIV)-inducing factor from the female genital tract activates HIV-1 gene expression through the kappaB enhancer. J Infect Dis 1998;178:1343-51
22. Firoz Mian M, Ashkar AA. Induction of innate immune responses in the female genital tract: friend or foe of HIV-1 infection? Am J Reprod Immunol 2011;65:344-51
23. Chan T, Barra NG, Lee AJ, Ashkar AA. Innate and adaptive immunity against herpes simplex virus type 2 in the genital mucosa. J Reprod Immunol 2011;88:210-8
24. Carr DJ, Tomanek L. Herpes simplex virus and the chemokines that mediate the inflammation. Curr Top Microbiol Immunol 2006;303:47-65
25. Ferreira VH, Nazli A, Khan G, et al. Endometrial epithelial cell responses to coinfecting viral and bacterial pathogens in the genital tract can activate the HIV-1 LTR in an NFfkappagB-and AP-1-dependent manner. J Infect Dis 2011;204:299-308
26. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002;185:45-52
27. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006;20:73-83
28. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371:2109-19
29. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008;358:1560-71
30. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010;362:427-39
31. Boily MC, Baggaley RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009;9:118-29
32. Fife KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS. Recurrence and resistance patterns of herpes simplex virus following cessation of. or years of chronic suppression with acyclovir. Acyclovir Study Group. J Infect Dis 1994;169:1338-41
33. Goldberg LH, Kaufman R, Kurtz TO, et al. Long-term suppression of recurrent genital herpes with acyclovir. A 5-year benchmark. Acyclovir Study Group. Arch Dermatol 1993;129:582-7
34. Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group. Genitourin Med 1997;73:110-6
35. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. J Infect Dis 1998;178:603-10
36. Conant MA, Schacker TW, Murphy RL, Gold J, Crutchfield LT, Crooks RJ. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS 2002;13:12-21
37. Beutner KR. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 1995;28:281-90
38. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest 1997;99:1092-7
39. Corey L, Ashley R. Prevention of herpes simplex virus type 2 transmission with antiviral therapy. Herpes 2004;11(Suppl. 3):170A-4A
40. Mugwanya KK, Baeten JM, Mugo N, Irungu E, Ngure K, Celum C. High-dose valacyclovir suppressive therapy results in greater reduction in plasma HIV-1 levels compared to standard dose acyclovir suppression among HIV-1/HSV-2 co-infected persons: a randomized, open-label, crossover trial. In: International AIDS Society. Rome, Italy; 2011
41. Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases. 2nd edn. Sydney: Elsevier; 1998
42. Van Dyke RB, Connor JD, Wyborny C, Hintz M, Keeney RE. Pharmacokinetics of orally administered acyclovir in patients with herpes progenitalis. Am J Med 1982;73:172-5
43. Gupta R, Hill EL, McClernon D, et al. Acyclovir sensitivity of sequential herpes simplex virus type 2 isolates from the genital mucosa of immunocompetent women. J Infect Dis 2005;192:1102-7
44. Reynolds SJ, Risbud AR, Shepherd ME, et al. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis 2003;187:1513-21
45. Brown EL, Wald A, Hughes JP, et al. High risk of human immunodeficiency virus in men who have sex with men with herpes simplex virus type 2 in the EXPLORE study. Am J Epidemiol 2006;164:733-41
46. Vanpouille C, Lisco A, Derudas M, et al. A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2. J Infect Dis 2010;201:635-43
47. Lisco A, Vanpouille C, Tchesnokov EP, et al. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpes virus-infected human tissues. Cell Host Microbe 2008;4:260-70
48. Derudas M, Carta D, Brancale A, et al. The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition. J Med Chem 2009;52:5520-30
49. Lisco A, Vanpouille C, Margolis L. A missed point in deciphering the viral synergy between herpes simplex virus and HIV. Lancet Infect Dis 2009;9:522-3
50. Vanpouille C, Lisco A, Margolis L. Acyclovir: a new use for an old drug. Curr Opin Infect Dis 2009;22:583-7
51. Koelle DM, Schomogyi M, Corey L. Antigen-specific T cells localize to the uterine cervix in women with genital herpes simplex virus type 2 infection. J Infect Dis 2000;182:662-70
52. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep 2002;51:1-78
53. Corey L, Nahmias AJ, Guinan ME, Benedetti JK, Critchlow CW, Holmes KK. A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med 1982;306:1313-9
54. Luby JP, Gnann JW Jr, Alexander WJ, et al. A collaborative study of patient-initiated treatment of recurrent genital herpes with topical acyclovir or placebo. J Infect Dis 1984;150:1-6
55. Spruance SL, Crumpacker CS, Schnipper LE, et al. Early, patient-initiated treatment of herpes labialis with topical 10% acyclovir. Antimicrob Agents Chemother 1984;25:553-5
56. Spruance SL, Schnipper LE, Overall JC Jr, et al. Treatment of herpes simplex labialis with topical acyclovir in polyethylene glycol. J Infect Dis 1982;146:85-90
57. Freeman DJ, Sheth NV, Spruance SL. Failure of topical acyclovir in ointment to penetrate human skin. Antimicrob Agents Chemother 1986;29:730-2
58. Yeo JM, Fiddian AP. Acyclovir in the management of herpes labialis. J Antimicrob Chemother 1983;12(Suppl. B):95-103
59. Spruance SL, Freeman DJ, Sheth NV. Comparison of foscarnet cream, acyclovir cream, and acyclovir ointment in the topical treatment of experimental cutaneous herpes simplex virus type 1 infection. Antimicrob Agents Chemother 1986;30:196-8
60. McKeough MB, Spruance SL. Comparison of new topical treatments for herpes labialis: efficacy of penciclovir cream, acyclovir cream, and n-docosanol cream against experimental cutaneous herpes simplex virus type 1 infection. Arch Dermatol 2001;137:1153-8
61. 09 AIDS Epidemic Update. 2009. See http://data.unaids.org/pub/Report/ 2009/JC1700_Epi_Update_2009_en.pdf (last checked 15 July 2010)
62. Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007;370:2127-37
63. Koelle DM, Corey L. Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med 2008;59:381-95
64. Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 2011;378:279-81
65. Karim QA, Karim SSA, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Sci Express 2010;10.1126:1
66. Cates W Jr. After CAPRISA 004: time to re-evaluate the HIV lexicon. Lancet 2010;376:495-6
67. Network MT. MTN Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women. Pittsburgh, PA, 2010
68. Consortium F. FACTS 001 Consortium Home Page; 2011
69. Schwartz JL, Rountree RW, Kashuba ADM, et al. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One 2011;6:e25974
70. Andrei G, Lisco A, Vanpouille C, et al. Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe 2011;10:379-89
71. Graciela A, Lisco A, Vanpouille C, et al. Explaining the CAPRISA 004 results: Tenofovir as a Double-Targeted HIV-1/HSV-2 Antiviral. Rome: IAS, 2011
72. Schwartz JL, Poindexter A, Wheeless A, Mauck CK, Callahan MM. Safety evaluation of 1% tenofovir gel in healthy men. Int J STD AIDS 2009;20:384-6
73. Thurman AR, Clark MR, Doncel GF. Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect Dis Obstet Gynecol 2011;2011:429403
74. McMahon MA, Parsons TL, Shen L, Siliciano JD, Siliciano RF. Consistent inhibition of HIV-1 replication in CD4{thorn} T cells by acyclovir without detection of human herpesviruses. J Virol 2011;85:4618-22
75. Kenney J, Aravantinou M, Singer R, et al. An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One 2011;6:e15835
76. Haraguchi Y, Sakurai H, Hussain S, Anner BM, Hoshino H. Inhibition of HIV-1 infection by zinc group metal compounds. Antiviral Res 1999;43:123-33
77. Kumel G, Schrader S, Zentgraf H, Daus H, Brendel M. The mechanism of the antiherpetic activity of zinc sulphate. J Gen Virol 1990;71(Pt 12):2989-97
78. Arens M, Travis S. Zinc salts inactivate clinical isolates of herpes simplex virus in vitro. J Clin Microbiol 2000;38:1758-62
79. Whaley KJ, Hanes J, Shattock R, Cone RA, Friend DR. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Antiviral Res 2010;88(Suppl. 1):S55-66